Acadia Pharmaceuticals reported $131.9M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 131.9M 19.38M
ALKERMES ALKS:US 217.86M 5.53M
Alnylam Pharmaceuticals ALNY:US $ 184.01M 6.38M
Biogen BIIB:US $ 2105.1M 327.2M
Biomarin Pharmaceutical BMRN:US $ 410.67M 8.28M
Bristol Myers Squibb BMY:US $ 9210M 33M
Corcept Therapeutics CORT:US $ 102.07M 9.63M
Eisai 4523:JP Y 136858M 3305M
Eli Lilly And LLY:US $ 5057.5M 680.4M
Intercept Pharmaceuticals ICPT:US $ 71.45M 16.38M
Intra Cellular Therapies ITCI:US $ 31.84M 8.71M
Johnson & Johnson JNJ:US $ 16101M 273M
Marinus Pharmaceuticals MRNS:US 13.02M 11.5M
Moderna Inc MRNA:US 3.37B 1.68B
Neurocrine Biosciences NBIX:US $ 373.4M 67.4M
Pfizer PFE:US $ 19071M 3420M
Ptc Therapeutics PTCT:US $ 155.89M 17.29M
Sarepta Therapeutics SRPT:US $ 195.69M 16.3M
Seattle Genetics SGEN:US $ 391.4M 52.57M
Ultragenyx Pharmaceutical RARE:US $ 81.07M 7.24M
Vertex Pharmaceuticals VRTX:US $ 1934.4M 82.7M
YTE INCY:US $ 866.16M 170.14M